2018 FDA Tides Harvest

Pharmaceuticals. 2019;12(2):52 DOI 10.3390/ph12020052

 

Journal Homepage

Journal Title: Pharmaceuticals

ISSN: 1424-8247 (Print)

Publisher: MDPI AG

LCC Subject Category: Medicine: Pharmacy and materia medica

Country of publisher: Switzerland

Language of fulltext: English

Full-text formats available: PDF, HTML

 

AUTHORS


Danah Al Shaer (KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa)

Othman Al Musaimi (KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa)

Fernando Albericio (School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa)

Beatriz G. de la Torre (KRISP, School of Laboratory of Medicine and Medical Science, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa)

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 11 weeks

 

Abstract | Full Text

In 2018, the United States Food and Drug Administration (FDA) approved a total of 59 new drugs, three of them (5%) are TIDES (or also, -tides), two oligonucleotides and one peptide. Herein, the three TIDES approved are analyzed in terms of medical target, mode of action, chemical structure, and economics.